Compare Johnson & Johnson (JNJ) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Wynn Resorts, Limited — how do they compare? Johnson & Johnson trades at $250.27 (market cap $598.96B), while Wynn Resorts, Limited trades at $95.17 (market cap $9.93B). The key difference: Johnson & Johnson is far larger — about 60.3× Wynn Resorts, Limited's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | WYNN | |
|---|---|---|
Market Cap | $598.96B | $9.93B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $133.34 |
52-Week Low | $164.36 | $94.78 |
Enterprise Value | $631.90B | $20.29B |
Dividend Yield | 2.15% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Wynn Resorts (WYNN) trades at $95.61, down 1.07% today, with a bearish technical signal and mixed earnings history including three consecutive quarterly misses. The company maintains strong revenue growth from $3.8B in 2022 to $7.1B in 2025, though net margins have compressed from 11.17% to 4.58% over the same period. Recent news highlights Q1 2026 earnings beating estimates with $1.25 EPS (Zacks Investment Research, May 7, 2026), while long-term debt remains elevated at $10.50B.
Analyst consensus is bullish with a $135.50 price target (64% buy ratings), but risks include high leverage, margin pressure from Macau competition, and geopolitical challenges for the UAE expansion. The stock offers 42% upside to consensus target if operational execution improves, though investors face volatility from earnings inconsistency and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
